GlycoMimetics Added To NASDAQ Biotechnology Index
December 15 2017 - 9:00AM
Business Wire
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that it will
be included in the NASDAQ Biotechnology Index® (NBI). The annual
re-ranking of the NASDAQ Biotechnology Index will be effective
prior to market upon on Monday, December 18, 2017.
The NASDAQ Biotechnology Index contains securities of
NASDAQ-listed companies classified according to the Industry
Classification Benchmark as either Biotechnology or
Pharmaceuticals, which also meet other eligibility criteria. The
NASDAQ Biotechnology Index is calculated under a modified
capitalization-weighted methodology.
For more information about the NBI, please see
https://indexes.nasdaqomx.com/Index/Overview/NBI.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' first
drug candidate, rivipansel, a pan-selectin antagonist, is being
developed for the treatment of vaso-occlusive crisis in sickle cell
disease and is being evaluated in a Phase 3 clinical trial being
conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly-owned drug candidate, GMI-1271, a
specific E-selectin antagonist, has been evaluated in a Phase 1/2
clinical trial as a potential treatment for AML and is currently
being evaluated in an ongoing Phase 1 clinical trial for the
treatment of multiple myeloma. The U.S. Food and Drug
Administration has granted GMI-1271 Breakthrough Therapy
designation for the treatment of adult AML patients with
relapsed/refractory disease. GlycoMimetics has also conducted
a Phase 1 clinical trial with a third drug candidate, GMI-1359, a
combined CXCR4 and E-selectin
antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171215005277/en/
GlycoMimetics, Inc.Investor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Sep 2023 to Sep 2024